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Abstract
Background: Chronic inflammation is a characteristic of Alzheimer's disease (AD). An interaction
associated with the risk of AD has been reported between polymorphisms in the regulatory
regions of the genes for the pro-inflammatory cytokine, interleukin-6 (IL-6, gene: IL6), and the anti-
inflammatory cytokine, interleukin-10 (IL-10, gene: IL10).
Methods: We examined this interaction in the Epistasis Project, a collaboration of 7 AD research
groups, contributing DNA samples from 1,757 cases of AD and 6,295 controls.
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Journal of Neuroinflammation 2009, 6:22 http://www.jneuroinflammation.com/content/6/1/22Results: We replicated the interaction. For IL6 rs2069837 AA × IL10 rs1800871 CC, the synergy
factor (SF) was 1.63 (95% confidence interval: 1.10–2.41, p = 0.01), controlling for centre, age,
gender and apolipoprotein E ε4 (APOEε4) genotype. Our results are consistent between North
Europe (SF = 1.7, p = 0.03) and North Spain (SF = 2.0, p = 0.09). Further replication may require a
meta-analysis. However, association due to linkage disequilibrium with other polymorphisms in the
regulatory regions of these genes cannot be excluded.
Conclusion: We suggest that dysregulation of both IL-6 and IL-10 in some elderly people, due in
part to genetic variations in the two genes, contributes to the development of AD. Thus,
inflammation facilitates the onset of sporadic AD.
Background
Alzheimer's disease (AD) is accompanied by a chronic
inflammatory process, including activation of microglia
and astrocytes that express pro-inflammatory cytokines
[1,2]. It is unclear to what extent this inflammation is a
reaction to the pathology of AD, and to what extent it con-
tributes to the onset or progression of the disease.
Two multi-functional cytokines, interleukin-6 (IL-6) and
interleukin-10 (IL-10), may be relevant to this question.
IL-6 is a potent pro-inflammatory cytokine [3], while IL-
10 acts to limit inflammation in the brain [4]. Both are
produced by activated microglia and astrocytes [3,4]. Two
single nucleotide polymorphisms (SNPs), rs1800795 (-
174G/C) and rs1800896 (-1082G/A), in the regulatory
regions of the genes, IL6 and IL10, respectively, have been
widely studied. However, the ongoing AlzGene meta-
analyses of the two SNPs [5]http://www.alzforum.org/
res/com/gen/alzgene/ are both currently negative (4 July
2009): pooled odds ratios for Caucasians in single-locus
analyses of IL6-174C versus G alleles = 0.93 (95% confi-
dence interval: 0.79–1.08, 14 studies) and of IL10-1082G
versus A alleles = 0.91 (0.74–1.11, eight studies). Our own
meta-analyses, both by allele and by genotype, confirmed
these results and also indicated a high degree of heteroge-
neity among the studies (p < 0.05 in seven out of eight
analyses, data not shown). Such inconsistencies may be
due to study differences, e.g. in design or technical or ana-
lytical approach. However, the heterogeneity remained in
six out of eight analyses after altogether four studies with
controls in Hardy-Weinberg disequilibrium were
removed. Alternatively, the heterogeneity may reflect true
population differences, such as in interactions with other
factors, including other genes. Such diverse results have
been described as a marker of epistasis [6,7], i.e. where the
effect of one polymorphism depends on the genotype at
another locus.
Infante et al (2004) [8] reported an interaction between
IL6-174G/C and IL10-1082G/A associated with the risk of
AD. We therefore set out to replicate this result in the
Epistasis Project.
The Epistasis Project
Sporadic Alzheimer's disease (AD) is a complex disease,
with over 50% heritability [9]. This suggests that its study
requires the investigation of interactions between risk fac-
tors, particularly genetic factors. The Epistasis Project stud-
ies such interactions, mainly those between distinct
genetic loci, i.e. epistasis. The project is a collaboration of
seven AD research groups: Bonn, Bristol, Nottingham,
OPTIMA, Oviedo, Rotterdam and Santander (Table 1).
The project aims: first, to replicate genetic interactions
that have been reported to affect the risk of sporadic AD;
second, to explore other polymorphisms in the relevant
genetic regions, ultimately to reveal the true risk loci. The
overriding object is to gain insights into AD causality.
However, interactions can only be reliably studied with
sufficient statistical power and careful study design. The
project therefore has these characteristics:-
1. Power
The project has 1,757 cases of AD and 6,295 elderly con-
trols. These numbers give 99.9% power to detect an SF
[10] of 2 between two polymorphisms, each with a minor
allele frequency of 20%, when controlling for individual
centres (2 below). They give 89.8% power or 48.6%
power to detect SFs of 1.5 or 1.25, respectively. Quality
control of genotyping reduces the numbers somewhat,
depending on the polymorphism.
2. Selection of sample-sets
Only sample-sets drawn from narrow geographical
regions with relatively homogeneous, Caucasian popula-
tions have been chosen, from seven AD research centres
(Table 1 and Additional file 1).
3. Sample characterisation
Cases of AD are either confirmed at autopsy as "definite"
or "probable" by CERAD criteria [11], or clinically diag-
nosed as "probable AD" by NINCDS-ADRDA criteria [12].
Controls are either screened as free of cognitive impair-
ment, or confirmed at autopsy as free of pathology con-
sistent with AD or other dementias.Page 2 of 9
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Only cases and controls drawn from the same region are
compared, thus controlling for geographical differences,
e.g. between North and South Europe.
5. Candidate interactions
Interactions are studied that have prior evidence of an
association with AD and a plausible biological hypothe-
sis. Interactions with age (± 75 years), gender and apoli-
poprotein E ε4 (APOEε4) genotype are also examined.
6. Analytical methods
Logistic regression and SF [10] analyses are used. All anal-
yses are controlled for age, gender and APOEε4 genotype.
All pooled analyses are also controlled for centre. There is
thus no question of controls from one centre (e.g., Rotter-
dam) being compared with AD cases from another region.
Controlling for centre also reduces the relative influence
of large subgroups, such as Rotterdam controls, in the
pooled result. Where pooled analyses yield significant
results, the seven individual centres are also examined for
associations with AD, for heterogeneity, and for power to
detect the interaction.
Table 1 gives the basic characteristics of the seven sample-
sets. See Additional file 1 for further information.
To select the interactions for study, a survey of over 100
published claims and suggestions of epistasis in sporadic
AD was undertaken [13]. The interactions finally chosen
are involved in various networks that are widely consid-
ered to contribute to the development of AD: lipid metab-
olism [14], β-amyloid metabolism [15], oxidative stress
[16], inflammation [1], insulin metabolism [17] and
homocysteine metabolism [18]. Positive results should
therefore deliver insights into the causes of AD.
Methods
Basic information on the 1,757 cases of AD and the 6,295
controls from the seven centres is given above and in
Table 1, and fuller details are provided in Additional file
1.
Genotyping for the six centres other than Rotterdam was
performed at the Wellcome Trust Sanger Institute, using
the iPLEX Gold assay (Sequenom Inc.). Whole genome
amplified DNA was used for 82% of samples; genomic
DNA was used for the 18% of samples that were not suit-
able for whole genome amplification. A Sequenom iPLEX,
designed for quality control purposes, was used to assess
genotype concordance between genomic and whole
genome amplified DNA for 168 individuals. Assays for all
SNPs were designed using the eXTEND suite and MassAR-
Table 1: Sample-sets used in the Epistasis Project
Group Geographical Region* Subjects† Numbers % women p (AD vs controls) Median age‡ 
(interquartile range)
p (AD vs controls)
Bonn Bonn and Mainz, 
Germany
Clinical AD 259 61.4 71.0 (65.1–77.5)
Screened controls 232 56.9 0.31 67.8 (64.4–76.1) 0.11
Bristol South-West England Autopsy AD 200 45.0 80.4 (75.6–86.0)
Autopsy controls 57 40.4 0.55 77.9 (72.8–82.9) 0.12
Nottingham Cambridge, England Autopsy AD 104 48.1 78.7 (70.8–84.6)
Autopsy controls 107 34.6 0.051 72.5 (65.6–80.0) < 0.001
OPTIMA Oxford, England Autopsy AD 163 54.6 79.5 (72.4–85.2)
Clinical AD 87 54.0 79.1 (73.4–84.8)
Screened controls 261 53.6 0.93 78.9 (72.9–83.8) 0.54
Oviedo Asturias, Spain Clinical AD 202 69.8 78.4 (74.8–82.8)
Screened controls 131 61.8 0.15 69.7 (63.5–74.5) < 0.001
Rotterdam Rotterdam 
(Ommord), the 
Netherlands
Clinical AD 391 74.9 86.6 (82.2–91.6)
Screened controls 5,111 57.7 < 0.001 76.9 (71.7–83.0) < 0.001
Santander Cantabria, Spain Clinical AD 351 65.0 75.5 (70.8–78.9)
Screened controls 396 68.9 0.27 80.9 (74.7–85.6) < 0.001
Totals Total AD 1,757 62.4 79.0 (73.0–85.2)
Total controls 6,295 57.7 76.9 (71.3–83.0)
AD = Alzheimer's disease
*from which the samples were drawn.
†Clinical AD cases were diagnosed as "probable AD" by NINCDS-ADRDA criteria [12]; autopsy AD cases were diagnosed as "definite" or 
"probable" by CERAD criteria [11]; screened controls were free of cognitive impairment; autopsy controls were free of pathology consistent with 
AD or other dementias; all controls were ≥ 60 years of age.
‡Age at death or last examination.Page 3 of 9
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Samples were amplified in multiplexed PCR reactions
before allele specific extension. Allelic discrimination was
obtained by analysis with a MassARRAY Analyzer Com-
pact mass spectrometer. Genotypes were automatically
assigned and manually confirmed using MassArray Typer-
Analyzer software version 4.0 (Sequenom Inc.). Gender
markers were included in all iPLEX assays as a quality con-
trol metric for confirmation of plate/sample identity.
Genotyping of SNPs rs1800871, rs2069837 and
rs3024505 was carried out using the KASPar technology
by KBioscience http://www.kbioscience.co.uk.
Genotyping in the Rotterdam cohort was done on Version
3 Illumina-Infinium-II HumanHap550 SNP array (Illu-
mina, San Diego, USA) and additionally, SNPs were
imputed using MACH software http://
www.sph.umich.edu/csg/abecasis/MACH/ with HapMap
CEU Release 22 as a reference [19]. The reliability of
imputation was estimated for each imputed SNP with the
ratio of expected and observed dosage variance (O/E
ratio). Only samples with high-quality extracted DNA
were genotyped; 5974 were available with good quality
genotyping data; 5502 of these had reliable phenotypes.
For the Epistasis Project, 52 genotyped SNPs and 116
imputed SNPs were selected.
We assessed associations with logistic regression models
and SF analysis [10], controlling for age, gender, APOEε4
and study centre, using R Version 2.6.1 (R Foundation for
Statistical Computing, Vienna, Austria). Heterogeneity
between centres was controlled by fitting a fixed effect cor-
responding to contrasts between the baseline centre and
the six other centres (having compared models with fixed-
and random-effect terms in centre, goodness of fit was
measured using Akaike's Information Criterion, which
favoured using fixed effects only). Where the overall SF
was significant at p < 0.05, the seven individual centres
and the two geographical regions, North Europe and
North Spain, were also examined. Power calculations
were by SF analysis. Meta-analyses were performed using
the random-effect method of DerSimonian and Laird [20]
and the heterogeneity test of Armitage [21]. Comparisons
of allelic frequencies between North Spain and North
Europe were by Fisher's exact test. We compared the medi-
ans of the age distributions of AD and control groups
using the Wilcoxon-Mann-Whitney test. Linkage disequi-
librium data were estimated using the R genetics library
http://cran.r-project.org/web/packages/genetics/
index.html. All tests of significance were two-sided.
Results
We replicated the interaction reported by Infante et al
(2004) [8] between IL6 rs1800795 (-174G/C) and IL10
rs1800896 (-1082G/A) (below). In the Rotterdam cohort,
we examined altogether five IL6-related SNPs, rs1800797,
rs1800795, rs2069837, rs2069840 and rs2069845, and
four IL10-related SNPs, rs1800896, rs1800871,
rs3024498 and rs3024505. In that preliminary study, we
found that the strongest interactions were seen between
IL6 rs2069837 (intron 2 A/G) and IL10 rs1800871 (-
819C/T) and between IL6 rs2069837 and IL10 rs3024505
(3' C/T) (data not shown). We therefore studied the five
SNPs shown in Table 2 in all seven sample-sets.
Hardy-Weinberg analysis was performed for the five SNPs
of Table 2 in both cases and controls of the Rotterdam
samples, genotyped by Rotterdam, and of the samples
from the other six centres, genotyped by the Sanger Insti-
tute. As expected by chance, one of these 20 analyses
resulted in disequilibrium: IL6-174G/C in AD cases of the
six centres (p = 0.02). The two IL6 SNPs were in linkage
disequilibrium (LD), as were the three IL10 SNPs (Table
2). The allelic frequencies differed significantly between
North Europe (Bonn, Bristol, Nottingham, OPTIMA and
Rotterdam) and North Spain (Oviedo and Santander) in
four out of the five SNPs (Table 2).
Table 2: Studied SNPs
Gene SNP Minor allele frequency in controls LD in controls
North
Europe
North
Spain
Difference
(p)
With D' r2
IL6 rs1800795 -174G/C 41.1% (C) 32.8% (C) < 0.0001 rs2069837 0.998 0.055
rs2069837 Intron 2 A/G 7.3% (G) 9.3% (G) 0.03
IL10 rs1800896 -1082G/A 50.7% (G) 43.1% (G) < 0.0001 rs1800871 0.999 0.296
rs3024505 0.988 0.191
rs1800871 -819C/T 22.5% (T) 26.7% (T) 0.002 rs3024505 0.999 0.058
rs3024505 3' C/T 16.6% (T) 14.2% (T) 0.06
SNP = single nucleotide polymorphism; LD = linkage disequilibrium; D' = ratio of observed LD to maximum possible LD; r = correlation coefficient; 
IL6 and IL10 = the genes for interleukin-6 and interleukin-10, respectively.Page 4 of 9
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interactions generated between the two IL6 SNPs and the
three IL10 SNPs in our overall dataset (Table 3), control-
ling for centre, age, gender and APOEε4 genotype (as in all
association analyses). Three of the six interactions were
associated with AD: SF p < 0.05. The first interaction
shown in Table 3 is effectively identical to that reported by
Infante et al 2004 [8]; we have merely reversed the first
genotype, i.e. CC rather than GC + GG, to give an SF of
1.56, rather than its inverse, 0.64, for easier comparison
with the other interactions. The two IL6 genotypes shown
in Table 3 were in LD (p < 0.0001), as were the three IL10
genotypes (p < 0.0001). The interaction between IL6
intron 2 AA and IL10-819CC was slightly the strongest: SF
= 1.63 (95% confidence interval = 1.10–2.41, p = 0.01).
All further analysis was therefore restricted to that interac-
tion.
Table 4 shows the effect of each of the two factors in that
interaction on the association with AD of the other factor.
The presence of IL10-819CC changed the association of
IL6 intron 2 AA with AD from negative (odds ratio = 0.86,
p = 0.30) to risk (odds ratio = 1.38, p = 0.02), while the
presence of the latter removed the protective association
of the former (odds ratio = 0.63, p = 0.01, changed to 1.08,
p = 0.32).
There was significant heterogeneity between the centres,
and the interaction was only significant in one of the
seven centres, Rotterdam, with an SF of 3.0 (95% confi-
dence interval = 1.6–5.8, p = 0.0007). But the power to
detect an SF of 1.6 was low in each centre, ranging from
below 10% to 40%. The results for North Europe (SF =
1.7, p = 0.03) and for North Spain (SF = 2.0, p = 0.09)
were consistent (Table 5).
Results were similar for men as for women (data not
shown). The interaction was slightly stronger in older sub-
jects: SF for > 75 years = 1.71 (1.05–2.78, 0.03); SF for <
75 years = 1.27 (0.56–2.87, 0.57). However, there was no
3-way interaction with age. Nor did we find a significant
interaction with APOEε4.
Discussion
In our whole dataset of over 7,500 samples, we have rep-
licated both the interaction reported by Infante et al 2004
[8] and also that found in our preliminary study in the
Rotterdam dataset, between SNPs of IL6 and IL10 (Table
3). Both interactions gave significant SFs of approximately
1.6. There was significant heterogeneity between centres,
which was unsurprising since only two, Rotterdam and
Santander, had > 20% power to detect these interactions.
But the results for the two main regions, North Europe
and North Spain, were consistent (Table 5). We conclude
that this is likely to be a true effect, but not a very strong
one. As in any example of true epistasis, the presence or
absence of one factor critically influenced the effect of the
other (Table 4).
Further replication will require a dataset at least as large,
with appropriate statistical control for differences
between individual sample-sets. Underpowered studies
are unhelpful, since chance can produce misleading
results in such cases. This criticism may apply to a previ-
ous study of this interaction that had power of < 2% to
detect it. Even the large Rotterdam Study, with 395 cases
of AD and 5,111 controls, only had 40% power to detect
this interaction. Thus, further replication may require a
meta-analysis.
IL-6 in age-related decline and in AD
There is much evidence that chronic, low-grade overex-
pression of IL-6 contributes to age-related decline. Blood
levels of IL-6 can rise with age in humans [22-24]. Raised
levels are associated with various age-related conditions,
including risk of cognitive decline in some studies
[25,26], but not in all [27]. Raised levels have been con-
sistently associated with increased mortality in several
Table 3: Potential interactions between IL6 SNPs and IL10 SNPs in the risk of AD
Interaction Numbers Adjusted*
synergy factor(95% CI, p)
IL6 × IL10 Controls AD cases
rs1800795 CC × rs1800896 G+ 6153 1557 1.56 (1.02–2.38, 0.04)
rs1800795 CC × rs1800871 CC 6158 1514 1.25 (0.86–1.80, 0.25)
rs1800795 CC × rs3024505 T+ 6190 1546 1.11 (0.75–1.64, 0.60)
rs2069837 AA × rs1800896 G+ 6126 1437 1.37 (0.89–2.11, 0.16)
rs2069837 AA × rs1800871 CC 6150 1442 1.63 (1.10–2.41, 0.01)
rs2069837 AA × rs3024505 T+ 6172 1429 1.55 (1.02–2.36, 0.04)
IL6 and IL10 = the genes for interleukin-6 and interleukin-10, respectively; SNPs = single nucleotide polymorphisms; AD = Alzheimer's disease; CI = 
confidence interval; G+ and T+ group the genotypes, GA+GG and CT+TT, respectively; APOEε4 = apolipoprotein E ε4.
*All analyses controlled for centre, age, gender and APOEε4 genotype.Page 5 of 9
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been associated with various conditions considered to be
risk factors for dementia and/or AD: subclinical and clin-
ical cardiovascular disease and the risk thereof [32-34],
type 2 diabetes and its risk [35,36], psychological stress
[37] and the damage following stroke (IL-6 also increased
in CSF) [38,39].
Further, raised blood levels of IL-6 have often been asso-
ciated with AD [40-42] and also with the risk of AD [43],
although not in all studies [44,45]. Post-mortem studies,
although small, have generally reported increased IL-6
levels or changed IL-6 distribution in AD brain [46-49],
with one exception [50]. IL-6 was found not only in
plaques, but also around the bodies of isocortical neu-
rones, only in AD [46]. This evidence and that above sug-
gest that dysregulation of IL-6 contributes to the
development of AD.
A potential interaction between IL6 and IL10
Both IL-6 and IL-10 are produced by activated microglia
and astrocytes (reviewed in [3,4]). However, in contrast to
IL-6, IL-10 acts to limit inflammation in the brain. IL-10
inhibits the production of IL-6 [51,52] and its receptor
[53]. Thus, certain combinations of genetic variants of IL6
and IL10, i.e. those associated with high production of IL-
6 combined with those associated with low production of
IL-10, may contribute to the dysregulation of inflamma-
tion. High heritability (> 50%) has been reported for in
vitro stimulated production of both IL-6 and IL-10 [54].
The functions of two of our studied SNPs, IL6 intron 2 A/
G and IL10 3' C/T have not yet been investigated. Thus we
cannot rule out that they might have effects on transcrip-
tion or post-transcriptional processing. Alternatively, they
may be in linkage disequilibrium with other, functional
variants. On the other hand, studies of IL6-174G/C
[55,56], of IL10-819C/T [57] and of IL10-1082G/A [58-
60] have reported that these SNPs affect transcription or
are in linkage disequilibrium with those that do. How-
ever, it may be premature to designate any particular alle-
les as high or low producers, since there have been
contrasting results for the effects of IL6-174G/C and IL10-
1082G/A on transcription, on in vitro stimulated produc-
tion and on blood levels of the respective proteins. But
most studies have associated the IL10-1082GG genotype
at least with higher in vitro stimulated production of IL-10
[61-64], although not all, [65,66] and results have varied
with experimental conditions [64,66]. It appears that sev-
eral SNPs in the regulatory regions of each gene affect
transcription in an interactive and tissue-specific manner
Table 4: Odds ratios of Alzheimer's disease for two IL6 and IL10 SNPs, stratified by each other
Odds ratio of AD for :- In the subset :- Numbers Adjusted* odds ratio of AD (95% CI, p)
Controls AD cases
IL6 IL10 AA: 2158 AA: 518 0.86 (0.64–1.15, 0.30)
rs2069837 rs1800871 T+ G+: 348 G+: 87
AA vs G+ IL10 AA: 3099 AA: 724 1.38 (1.06–1.79, 0.02)
rs1800871 CC G+: 545 G+: 113
IL10 IL6 CC: 545 CC: 113 0.63 (0.44–0.91, 0.01)
rs1800871 rs2069837 G+ T+: 348 T+: 87
CC vs T+ IL6 CC: 3099 CC: 724 1.08 (0.93–1.25, 0.32)
rs2069837 AA T+: 2158 T+: 518
IL6 and IL10 = the genes for interleukin-6 and interleukin-10, respectively; AD = Alzheimer's disease; CI = confidence interval; G+ and T+ group the 
genotypes, GA+GG and CT+TT, respectively; APOEε4 = apolipoprotein E ε4.
*All analyses controlled for centre, age, gender and APOEε4 genotype.
Table 5: Interaction between IL6 rs2069837 AA vs G+ and IL10 rs1800871 CC vs T+, by region
Region Power* Adjusted† synergy factor (95% CI, p) in the risk of AD
North Europe‡ 64% 1.7 (1.05–2.6, 0.03)
North Spain‡ 37% 2.0 (0.9–4.4, 0.09)
All 76% 1.6 (1.1–2.4, 0.01)
IL6 and IL10 = the genes for interleukin-6 and interleukin-10, respectively; G+ and T+ group the genotypes, GA+GG and CT+TT, respectively; CI = 
confidence interval; AD = Alzheimer's disease; APOEε4 = apolipoprotein E ε4.
*To detect a synergy factor of 1.6 (as in the overall dataset) at 0.05.
†All analyses controlled for centre, age, gender and APOEε4 genotype.
‡North Europe = Rotterdam, Bonn, OPTIMA, Nottingham and Bristol; North Spain = Santander and Oviedo.Page 6 of 9
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bination of IL10 -1082G+/-819CC has a slightly stronger
interaction with IL6 than that of either SNP alone (data
not shown).
Conclusion
We conclude that an interaction between IL-6 and IL-10 is
plausible; that dysregulation of the two genes contributes
to chronic low-grade inflammation in some elderly peo-
ple and thus to the risk of AD; and that certain combina-
tions of genetic variants in the regulatory regions of the
two genes are conducive to this dysregulation. But in view
of the linkage disequilibrium in the region of each gene
(Table 2), we cannot conclude that we have yet found the
true risk polymorphisms. However, we suggest that our
results are consistent with the contribution of inflamma-
tion to the onset of AD.
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